Cargando…
Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial
BACKGROUND: Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plas...
Autores principales: | Boyle, Andrew James, Ferris, Peter, Bradbury, Ian, Conlon, John, Shankar-Hari, Manu, Rogers, Angela J., O’Kane, Cecilia M., McAuley, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175337/ https://www.ncbi.nlm.nih.gov/pubmed/35672834 http://dx.doi.org/10.1186/s13054-022-04025-w |
Ejemplares similares
-
Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials
por: Santhakumaran, Shalini, et al.
Publicado: (2019) -
Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials
por: Pienkos, Shaun M., et al.
Publicado: (2023) -
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial
por: McAuley, Daniel F, et al.
Publicado: (2012) -
The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial
por: McKelvey, Michael C., et al.
Publicado: (2023) -
Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury
por: McAuley, Daniel F, et al.
Publicado: (2013)